CXCL9 and neoplasm: Evaluation of TDLNs following IT CXCL9/10-DC therapy in KPL-3M tumor-bearing mice showed enhanced proliferation of both CD4+ and CD8+ T cells, ascertained by Ki67+ staining, and an increased T cell effector polarization, determined by CXCR3 expression (Figure 4A).